Tech Company Financing Transactions
Arnatar Therapeutics Funding Round
3E Bioventures, Eight Roads and F-Prime Capital participated in a $52 million Series A capital raise for Arnatar Therapeutics. The financing round was announced by the company on 8/25/2025.
Transaction Overview
Company Name
Announced On
8/25/2025
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series A
Investors
3E Bioventures (Lead Investor)
Eight Roads (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its DARGER� platform and pipeline of RNA therapeutics, which combine siRNA with upregulating ASOs to deliver medicines for cardiometabolic, liver, CNS, and kidney diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Diego, CA Undisclosed
USA
San Diego, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Founded by pioneers in RNA therapeutics, Arnatar is advancing a new era of programmable medicine. Our mission is to deliver precision RNA therapies that go beyond gene silencing--restoring critical protein function and offering long-term disease control. With deep discovery expertise, differentiated delivery, and a commitment to translating innovation into impact, we aim to improve outcomes across diseases where current treatments fall short.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xuehai Liang
Browse more venture capital transactions:
Prev: 8/25/2025: Soil Action venture capital transaction
Next: 8/25/2025: Interhuman AI venture capital transaction
Share this article
News on VC Transactions
We document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs